NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Biotechnology · USD

Veraxa Biotech AG (VRXA) Stock Analysis

Veraxa Biotech AG (VRXA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

VRXA

$1.03

−$0.03 (−2.83%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VRXA with… →

VRXA Key Statistics

As of Oct 22, 2026
Trading
Open
$1.08
Previous Close
$1.06
Day's Range
1.03–1.08
52-Week Range
0.99–27.36
Volume
171.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.19
Valuation
Market Cap
$145.65M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6,217.45
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.57
Financials (FY)
Revenue (FY)
$23.43K
Net Income (FY)
−$66.61M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
141.41M
1-Year Return
−90.17%
Dividend and dates
Avg Volume
270.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, VRXA closed at $1.03, −90.17% over 1 year.

Veraxa Biotech AG (VRXA) has a market capitalization of $145.65M.

In fiscal 2025, VRXA reported revenue of $23.43K.

VRXA Stock Return by Calendar Year

Veraxa Biotech AG (VRXA) return since Sep 2024: what $10,000 became

1 year
$10,000 $983
−90.17%
Since Sep 2024
$10,000 $1,033
−89.67%

If you had invested $10,000 in Veraxa Biotech AG (VRXA) at the close on September 30, 2024, the earliest close on record here, it would have been worth $1,033 at the close on October 22, 2026: −89.67% in total, −66.80% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−90.35%
2025+6.49%
2024 (partial year)+0.50%

As of October 22, 2026.

VRXA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$23.43K−$66.61M−284,359.2%
2024$0.00−$28.13M—
2023$0.00−$16.54M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$23.43K$15.46K−$66.22M−$66.61M−284,359.2%
2024$0.00$0.00−$28.92M−$28.13M—
2023$0.00—−$16.66M−$16.54M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Veraxa Biotech AG (VRXA) is capitalised at $145.65M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for VRXA is $1.03, dated October 22, 2026. That is −$0.03 (−2.83%) against the previous close. The 52-week range on file runs from $0.99 to $27.36. The latest close sits 4.04% above that 52-week low.

Financial Health

In fiscal 2025, Veraxa Biotech AG reported revenue of $23.43K. The same year closed with a net loss of $66.61M. Earnings per share on a trailing basis come to −0.57.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $23.43K in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 6,217.45 times revenue. On price-to-sales that is 469.1 times the Biotechnology median of 13.26. The medians here are taken across 607 Biotechnology companies that report the metric.

The trailing one-year total return is −90.17%. The stored price history starts on September 30, 2024, and the total return since then is −89.67%. Beta against the wider market is reported at 0.19. Annualized volatility over the trailing 2 years is 96.34%.

Growth & Income

No dividend is on file for VRXA.

The record holds one complete calendar year, 2025, which returned +6.49%. So far in 2026 the total return is −90.35%.

Peer Comparison

Veraxa Biotech AG (VRXA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Veraxa Biotech AG VRXA $145.65M —
Vertex Pharmaceuticals Incorporated VRTX $135.64B 31.0
Regeneron Pharmaceuticals, Inc. REGN $84.33B 20.3
Moderna, Inc. MRNA $80.90B —

The Biotechnology industry average P/E ratio is 16.6x. Veraxa Biotech AG has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$135.64B

 REGN

Regeneron Pharmaceuticals, Inc.

$84.33B

 MRNA

Moderna, Inc.

$80.90B

 ARGX

argenx SE

$55.07B

 ONC

BeOne Medicines AG

$43.49B

 RVMD

Revolution Medicines, Inc.

$40.23B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Veraxa Biotech AG

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Visit website →